These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20626844)

  • 1. CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.
    Boulton IC; Nwaka S; Bathurst I; Lanzer M; Taramelli D; Vial H; Doerig C; Chibale K; Ward SA
    Malar J; 2010 Jul; 9():202. PubMed ID: 20626844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRIMALDDI: a prioritized research agenda to expedite the discovery of new anti-malarial drugs.
    Ward SA; Boulton IC
    Malar J; 2013 Nov; 12():395. PubMed ID: 24191947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRIMALDDI: platform technologies and novel anti-malarial drug targets.
    Vial H; Taramelli D; Boulton IC; Ward SA; Doerig C; Chibale K
    Malar J; 2013 Nov; 12():396. PubMed ID: 24498961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Union's research policy: a moving target?
    Boelaert M; Matthys F; Henkens M; D'Alessandro U
    Trop Med Int Health; 2001 Nov; 6(11):843-4. PubMed ID: 11703836
    [No Abstract]   [Full Text] [Related]  

  • 5. Natural products as starting points for future anti-malarial therapies: going back to our roots?
    Wells TN
    Malar J; 2011 Mar; 10 Suppl 1(Suppl 1):S3. PubMed ID: 21411014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
    White NJ; Pongtavornpinyo W; Maude RJ; Saralamba S; Aguas R; Stepniewska K; Lee SJ; Dondorp AM; White LJ; Day NP
    Malar J; 2009 Nov; 8():253. PubMed ID: 19906307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
    Ashton TD; Devine SM; Möhrle JJ; Laleu B; Burrows JN; Charman SA; Creek DJ; Sleebs BE
    J Med Chem; 2019 Dec; 62(23):10526-10562. PubMed ID: 31385706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of the change in anti-malarial treatment policy: Peru.
    Williams HA; Vincent-Mark A; Herrera Y; Chang OJ
    Malar J; 2009 Apr; 8():85. PubMed ID: 19400953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current therapies and future possibilities for drug development against liver-stage malaria.
    Raphemot R; Posfai D; Derbyshire ER
    J Clin Invest; 2016 Jun; 126(6):2013-20. PubMed ID: 27249674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-malarial market and policy surveys in sub-Saharan Africa.
    Diap G; Amuasi J; Boakye I; Sevcsik AM; Pecoul B
    Malar J; 2010 Apr; 9 Suppl 1(Suppl 3):S1. PubMed ID: 20423536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Funding scrutiny could help set priorities for malaria.
    Senior K
    Lancet Infect Dis; 2008 May; 8(5):280. PubMed ID: 18499903
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploring the role of socioeconomic factors in the development and spread of anti-malarial drug resistance: a qualitative study.
    Anyanwu PE; Fulton J; Evans E; Paget T
    Malar J; 2017 May; 16(1):203. PubMed ID: 28521791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development: Holding out for reinforcements.
    Eisenstein M
    Nature; 2012 Apr; 484(7395):S16-8. PubMed ID: 22534526
    [No Abstract]   [Full Text] [Related]  

  • 15. An Overview of Available Antimalarials: Discovery, Mode of Action and Drug Resistance.
    Tang YQ; Ye Q; Huang H; Zheng WY
    Curr Mol Med; 2020; 20(8):583-592. PubMed ID: 32031068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MalDA, Accelerating Malaria Drug Discovery.
    Yang T; Ottilie S; Istvan ES; Godinez-Macias KP; Lukens AK; Baragaña B; Campo B; Walpole C; Niles JC; Chibale K; Dechering KJ; Llinás M; Lee MCS; Kato N; Wyllie S; McNamara CW; Gamo FJ; Burrows J; Fidock DA; Goldberg DE; Gilbert IH; Wirth DF; Winzeler EA;
    Trends Parasitol; 2021 Jun; 37(6):493-507. PubMed ID: 33648890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards malaria elimination in the Greater Mekong Subregion: perspectives from the World Health Organization.
    Manzoni G; Try R; Guintran JO; Christiansen-Jucht C; Jacoby E; Sovannaroth S; Zhang Z; Banouvong V; Shortus MS; Reyburn R; Chanthavisouk C; Linn NYY; Thapa B; Khine SK; Sudathip P; Gopinath D; Thieu NQ; Ngon MS; Cong DT; Hui L; Kelley J; Valecha NNK; Bustos MD; Rasmussen C; Tuseo L
    Malar J; 2024 Mar; 23(1):64. PubMed ID: 38429807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities.
    Whitty CJ; Chandler C; Ansah E; Leslie T; Staedke SG
    Malar J; 2008 Dec; 7 Suppl 1(Suppl 1):S7. PubMed ID: 19091041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The state of the art in anti-malarial drug discovery and development.
    Burrows JN; Chibale K; Wells TN
    Curr Top Med Chem; 2011; 11(10):1226-54. PubMed ID: 21401508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malaria: anti malarial resistance and policy ramifications and challenges.
    Kshirsagar NA
    J Postgrad Med; 2006; 52(4):291-3. PubMed ID: 17102549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.